IDIOPATHIC MEMBRANOUS NEPHROPATHY TREATMENT MARKET ANALYSIS

Idiopathic Membranous Nephropathy Treatment Market , By Drug Class (Alkylating Agents (Cyclophosphamide and Chlorambucil), Cyclic Peptides, Immunosuppressing Agents (Tacrolimus, Mycophenolate Mofetil, and Rituximab), Synthetic Adrenocorticotropic Hormone (ACTH) Analogue, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI3383
Formats :
Excel and PDF
Industry : Pharmaceutical

Idiopathic Membranous Nephropathy Treatment MarketSize and Trends

Global Idiopathic Membranous Nephropathy Treatment Market Drivers

Leading manufacturers are engaged in the manufacture of drugs for treatment of idiopathic membranous nephropathy. Increasing research and development activities related to newer treatment options is expected to support the global idiopathic membranous nephropathy treatment market growth over the forecast period. For instance, Novartis International AG has a potential drug, LNP023 (orally active factor B inhibitor), in phase II of clinical trials. The study is expected to be completed in June 2021. The drug is being tested on patients suffering from idiopathic membranous nephropathy.

Moreover, National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network and GlaxoSmithline are currently working together to understand the effect of combination therapy involving belimumab and rituximab on patients suffering from idiopathic membranous nephropathy. The phase II study started in December 2019 and is expected to finish in February 2025.

According to the New England Journal of Medicine, 2019, a clinical trial performed on patients suffering from membranous nephropathy to compare the efficacy of rituximab and cyclosporine, showed that 60% of the patients responded positively to the rituximab treatment. The remaining 40% patients did not show any response to the treatment. Therefore, there is more scope for developing alternative immunosuppressive therapies for a minor group of patients suffering from idiopathic membranous nephropathy and resistant to rituximab treatment. High incidence of idiopathic membranous nephropathy is expected to boost the global idiopathic membranous nephropathy treatment market growth over the forecast period.